CA3270902A1 - Combinaisons pharmaceutiques et leurs utilisations - Google Patents

Combinaisons pharmaceutiques et leurs utilisations

Info

Publication number
CA3270902A1
CA3270902A1 CA3270902A CA3270902A CA3270902A1 CA 3270902 A1 CA3270902 A1 CA 3270902A1 CA 3270902 A CA3270902 A CA 3270902A CA 3270902 A CA3270902 A CA 3270902A CA 3270902 A1 CA3270902 A1 CA 3270902A1
Authority
CA
Canada
Prior art keywords
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3270902A
Other languages
English (en)
Inventor
Garron Dodd
Cait BEDDOWS
Feiyue SHI
Callen Charles LUCAS-GOLDSMITH
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Melbourne filed Critical University of Melbourne
Publication of CA3270902A1 publication Critical patent/CA3270902A1/fr
Pending legal-status Critical Current

Links

CA3270902A 2022-11-28 2023-11-28 Combinaisons pharmaceutiques et leurs utilisations Pending CA3270902A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2022903599 2022-11-28

Publications (1)

Publication Number Publication Date
CA3270902A1 true CA3270902A1 (fr) 2024-06-06

Family

ID=

Similar Documents

Publication Publication Date Title
EP4215208A4 (fr) Association pharmaceutique et son utilisation
IL320856A (en) Pharmaceutical combinations and their uses
EP4165049A4 (fr) Psychoplastogènes d'isotryptamine et leurs utilisations
EP4230205A4 (fr) Composition pharmaceutique antitumorale et son application
EP4140480A4 (fr) Combinaison de médicaments et son utilisation
CA3266804A1 (fr) Composition pharmaceutique et son utilisation
EP4342492A4 (fr) Combinaison pharmaceutique et son utilisation
EP4364735A4 (fr) Composition pharmaceutique et son utilisation
EP4129282A4 (fr) Association pharmaceutique et son utilisation
CA3270902A1 (fr) Combinaisons pharmaceutiques et leurs utilisations
CA3273324A1 (fr) Combinaisons pharmaceutiques et leurs utilisations
HK40124257A (en) Pharmaceutical combinations and uses thereof
AU2022903599A0 (en) Pharmaceutical combinations and uses thereof
CA3304458A1 (fr) Combinaison pharmaceutique et utilisation
HK40081165A (en) Pharmaceutical combination comprising tno155 and nazartinib
HK40113484A (en) Pharmaceutical preparation and application thereof
AU2024368057A1 (en) Pharmaceutical composition and use thereof
CA3301973A1 (fr) Composition pharmaceutique et son utilisation
CA3298413A1 (fr) Composition pharmaceutique et utilisation associée
HK40103610A (en) Pharmaceutical combination and use thereof
CA3278393A1 (fr) Composition pharmaceutique et utilisation associée
HK40131600A (en) Pharmaceutical formulations and uses thereof
HK40099664A (en) Pharmaceutical composition and use thereof
CA3307498A1 (fr) Compositions pharmaceutiques et leurs utilisations
HK40089929A (zh) 药物制剂及其用途